Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2821)	9/17/2011 11:43:26 AM
From: rkrw	of 3027

I wouldn't begin to try to decipher the case! But perhaps others will chime in with something intelligent to add! The patents do expire in 2014, roughly 2 years after the case should be decided (before appeal), so my view is the case is material but not tremendously so should MNTA lose. The bigger event would be gaining final FDA approval without the need for a clinical trial. For all we know the FDA decision will drag up to and beyond the expiration, much as the Lovenox case did, for Teva and others anyway (i.p. would have expired in 2012).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next